Human menopausal gonadotropin-induced bioprosthetic valve thrombosis

Abstract

Bioprosthetic valve thrombosis (BPVT) is a rare but potentially life-threatening complication. Human menopausal gonadotropin (hMG) is commonly used for ovulation induction and has been associated with arterial and venous thrombosis. We reported a case of BPVT related to in vitro fertilization in a 39-year-old female, who underwent redo mitral valve replacement. To the best of our knowledge, this is the first case of hMG-induced BPVT in a young female patient.

Acute Bioprosthetic Mitral Valve Thrombosis: An Unfortunate Collision of Prothrombotic Risk Factors

“…Bioprosthetic valves tend to be the implant of choice in women of child-bearing age that require valve replacement. Despite the increasing worldwide use of assisted reproductive technologies over the past decade [Toner 2016;Kushnir 2017], including gonadotropin stimulation, which has been consistently and reproducibly associated with an elevated risk of vascular thrombosis [Gurunath 2018], there has been only one case report to date of bioprosthetic mitral valve thrombosis in a female patient undergoing IVF therapy [Abazid 2018]. Unfortunately, not only did our patient receive hormonal stimulation, she was ultimately found to also have protein C deficiency, an independent marker for thromboembolic phenomena.…”